Breaking News Instant updates and real-time market news.

MTSI

Macom

$12.59

-0.61 (-4.62%)

, SGMS

Scientific Games

$18.86

-1.83 (-8.84%)

19:06
05/07/19
05/07
19:06
05/07/19
19:06

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Macom (MTSI) up 7.9%... Scientific Games (SGMS) up 7.8%... Match Group (MTCH) up 7.7%... Electronic Arts (EA) up 7.2%... Avalara (AVLR) up 6.9%... Kinross Gold (KGC) up 6.5%... Outfront Media (OUT) up 6.3%... Qorvo (QRVO) up 5.5%... j2 Global (JCOM) up 3.8%... Plains All American (PAA) up 3.4%... Carrizo Oil (CRZO) up 3.3%... PCTEL (PCTI) up 3.3%... Papa John's (PZZA) up 2.7%... Two Harbors (TWO) up 2.3%... Jazz Pharma (JAZZ) up 1.9%... Beacon Roofing (BECN) up 1.7%... Parateum (TEUM) up 1.0%. DOWN AFTER EARNINGS: Inogen (INGN) down 25.0%... 2U (TWOU) down 16.7%... Supernus Pharma (SUPN) down 14.8%... 3D Systems (DDD) down 14.5%... Invitae (NVTA) down 14.2%... Livent Corp (LTHM) down 12.5%... Hi-Crush Partners (HCLP) down 6.1%... TripAdvisor (TRIP) down 5.5%... Opko Health (OPK) down 5.5%... Sprint (S) down 3.1%... Wingstop (WING) down 2.6%... Lyft (LYFT) down 1.6%. Movers as of 18:45ET.

MTSI

Macom

$12.59

-0.61 (-4.62%)

SGMS

Scientific Games

$18.86

-1.83 (-8.84%)

MTCH

Match Group

$60.36

-1.83 (-2.94%)

EA

Electronic Arts

$92.78

-0.16 (-0.17%)

AVLR

Avalara

$59.53

0.11 (0.19%)

KGC

Kinross Gold

$3.04

-0.03 (-0.98%)

OUT

Outfront Media

$24.00

0.03 (0.13%)

QRVO

Qorvo

$73.65

-0.67 (-0.90%)

JCOM

j2 Global

$85.59

-1.41 (-1.62%)

PAA

Plains All American

$23.47

0.03 (0.13%)

CRZO

Carrizo Oil & Gas

$11.14

-0.56 (-4.79%)

PCTI

PCTEL

$4.80

-0.13 (-2.64%)

PZZA

Papa John's

$51.37

-2.12 (-3.96%)

TWO

Two Harbors

$13.49

-0.11 (-0.81%)

JAZZ

Jazz Pharmaceuticals

$128.74

-4.21 (-3.17%)

BECN

Beacon Roofing

$37.63

-0.665 (-1.74%)

TEUM

Pareteum

$4.89

-0.29 (-5.60%)

INGN

Inogen

$90.97

-5.13 (-5.34%)

TWOU

2U

$59.99

-2.36 (-3.79%)

SUPN

Supernus

$36.98

-1.22 (-3.19%)

DDD

3D Systems

$10.59

-0.4 (-3.64%)

NVTA

Invitae

$23.80

-1.21 (-4.84%)

LTHM

Livent

$10.73

-0.24 (-2.19%)

HCLP

Hi-Crush Partners

$3.60

-0.04 (-1.10%)

TRIP

TripAdvisor

$54.92

-1.14 (-2.03%)

OPK

Opko Health

$2.36

-0.12 (-4.84%)

S

Sprint

$5.78

0.04 (0.70%)

WING

Wingstop

$76.17

0.01 (0.01%)

LYFT

Lyft

$59.38

-0.92 (-1.53%)

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 14

    May

  • 15

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 17

    May

  • 20

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 10

    Jun

  • 12

    Jun

  • 23

    Jun

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 06

    Aug

  • 13

    Nov

MTSI Macom
$12.59

-0.61 (-4.62%)

04/25/19
04/25/19
DOWNGRADE
Target $16

Neutral
Macom downgraded to Neutral from Buy at DA Davidson
As previously reported, DA Davidson analyst Mark Kelleher downgraded Macom to Neutral and lowered his price target to $16 from $20 after its negative Q2 earnings pre-announcement. The analyst says the outlook reflected "weakness in Datacenter and slowness by datacenter customers to qualify new transceiver solutions," even though the company forecasted the March quarter to be the "lowest quarter of the year", leading to a ramp in revenue toward the back half of FY19.
04/25/19
JEFF
04/25/19
DOWNGRADE
Target $15
JEFF
Hold
Macom downgraded to Hold after negative preannouncement at Jefferies
Jefferies analyst Mark Lipacis last night downgraded Macom to Hold from Buy and lowered his price target for the shares to $15 from $18. Following the negative preannouncement, the stock will "mark-time" until the company addresses three issues with investors: cash flow, forecasting, and stewardship of shareholder cash, Lipacis tells investors in a research note. Further, the analyst thinks this will be difficult to do without a permanent CFO. Nevertheless, Macom fits the profile of attractive acquisition candidates, which likely creates some downside share support, says Lipacis.
04/25/19
DADA
04/25/19
DOWNGRADE
DADA
Neutral
Macom downgraded to Neutral from Buy at DA Davidson
04/24/19
EVER
04/24/19
DOWNGRADE
EVER
In Line
Macom downgraded to In Line from Outperform at Evercore ISI
SGMS Scientific Games
$18.86

-1.83 (-8.84%)

11/16/18
JEFF
11/16/18
DOWNGRADE
Target $22
JEFF
Hold
Scientific Games downgraded to Hold from Buy at Jefferies
Jefferies analyst David Katz downgraded Scientific Games to Hold and cut his price target for the shares to $22 from $46. The changes at the company, some of which are of its own doing and some not, have "compiled to exacerbate the market-driven pressure on the shares," Katz tells investors in a research note. Scientific Games changed CEOs, lost a lawsuit which it expects to appeal, lost a significant systems contract and the high yield market has tightened on higher interest rates, which could mitigate the opportunity to refinance its 10% debt, says the analyst. He believes the pressure from these events is not likely to reverse in the near term. Overhangs, uncertainties and leverage "warrant a more conservative stance," says Katz.
12/14/18
JEFF
12/14/18
NO CHANGE
Target $22
JEFF
Hold
Jefferies sees 'mixed reaction' to Scientific Games shares from settlement
Scientific Games' $151.5M settlement of litigation with Shuffle Tech removes an overhang that has weighed on the stock over the past four months, albeit at the cost of the company's near term financial position and free cash flow generation, Jefferies analyst David Katz tells investors in a research note. Overall, the settlement provides clarity from a range of outcomes, which included the potential for no cash payment, says the analyst. As such. Katz expects a "mixed reaction" in the stock and keeps a Hold rating on Scientific Games with a $22 price target.
03/20/19
FBCO
03/20/19
INITIATION
Target $21
FBCO
Underperform
Scientific Games assumed with an Underperform at Credit Suisse
Credit Suisse analyst Ben Combes assumed coverage of Scientific Games with an Underperform rating and $21 price target.
11/12/18
DBAB
11/12/18
NO CHANGE
Target $26
DBAB
Hold
Scientific Games price target lowered to $26 from $45 at Deutsche Bank
Deutsche Bank analyst Carlo Santarelli lowered his price target for Scientific Games to $26 saying he does not believe there was much in the Q3 print "for investors to be overly excited about." Scientific Games "modestly outpaced" consensus forecasts, with the narrow beat stemming from an end-of-period sale of units from the participation base, Santarelli tells investors in a research note. He continues to see the company "experiencing core operational headwinds" and believes the current valuation is fair. The analyst reaffirms a Hold rating on Scientific Games.
MTCH Match Group
$60.36

-1.83 (-2.94%)

04/03/19
JEFF
04/03/19
NO CHANGE
Target $64
JEFF
Buy
Jefferies sees Match Group shares grinding, not flying, higher
While difficult to maintain the 30% growth experienced in 2018, Match Group should see sustainable mid to high teen revenue growth and high 30% margins going forward, Jefferies analyst Brent Thill tells investors in a research note. However, with the stock up 32% year-to-date, "further multiple expansion may prove difficult at these levels," adds the analyst. Nonetheless, Thill trusts Match's "history of quarterly execution" and the long-term "tailwinds at play. He expects the stock "to grind higher rather than fly higher" and keeps a Buy rating on the name with a $64 price target. It remains a top mid cap pick at Jefferies.
04/18/19
JEFF
04/18/19
NO CHANGE
Target $270
JEFF
Buy
IAC price target raised to $270 from $260 at Jefferies
Jefferies analyst Brent Thill raised his price target for IAC (IAC) to $270 from $260 and keeps a Buy rating on the shares. IAC remains a top mid cap pick and the stock remains undervalued, Thill tells investors in a research note. He estimates the company's non Match Group (MTCH) and Angi Homeservices (ANGI) businesses, which he says trade at a negative $3B value, will do more revenue than 40% of his coverage universe. Given IAC's history of creating value through corporate actions, the stock's discount "is surprising to us," says Thill.
02/11/19
JPMS
02/11/19
NO CHANGE
Target $250
JPMS
Overweight
IAC price target raised to $250 from $235 at JPMorgan
JPMorgan analyst Doug Anmuth raised his price target for IAC (IAC) to $250 following the company's Q4 results and initial 2019 guidance. The analyst remains positive on the shares with increased confidence in the trajectory of Vimeo and Dotdash offsetting his slightly lowered Angi Homeservices (ANGI) estimates. Anmuth continues to prefer IAC over Match Group (MTCH) and keeps an Overweight rating on the shares.
02/27/19
JEFF
02/27/19
NO CHANGE
Target $64
JEFF
Buy
Match Group remains a top mid cap pick despite recent rally at Jefferies
The Spring Break mode builds off of Tinder U and helps expand Match Group's reach into the college demographic, Jefferies analyst Brent Thill tells investors in a research note. While some will argue that Tinder growth is tapped out, the amount of paying subs, 4.3M, is still fewer than the incoming U.S. freshmen class, the analyst points out, whose data checks show continued strength. Thill says Match Group remains one of his top mid cap picks despite the 29% rally year-to-date. The analyst keeps a Buy rating on the shares with a $64 price target.
EA Electronic Arts
$92.78

-0.16 (-0.17%)

05/03/19
05/03/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Yeti (YETI) downgraded to Neutral from Buy at Goldman Sachs with analyst Alexandra Walvis saying the company's "strong" sales and brand momentum are now better understood by investors. 2. Electronic Arts (EA) downgraded to Neutral at MKM Partners on valuation with analyst Eric Handler saying the risk-reward on the stock appears to be "less compelling." 3. Cognizant (CTSH) downgraded to Market Perform from Outperform at William Blair, to Underweight from Neutral at JPMorgan, to Neutral from Buy at Goldman Sachs, to Perform from Outperform at Oppenheimer, to Sector Weight from Overweight at KeyBanc, to Neutral from Outperform at Wedbush and to Hold from Strong Buy at Needham after the company's earnings and guidance missed consensus estimates. 4. Target (TGT) downgraded to Market Perform from Outperform at Bernstein with analyst Brandon Fletcher saying he thinks Target's continued emphasis on growth over cost containment is a "less wise" stance at this point. 5. Achillion (ACHN) downgraded to Underweight from Equal Weight at Barclays with analyst Geoffrey Meacham seeing a lack of near- to mid-term catalysts that are capable of changing the story on the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/03/19
05/03/19
DOWNGRADE
Target $100

Neutral
Electronic Arts downgraded to Neutral at MKM Partners on valuation
As previously reported, MKM Partners analyst Eric Handler downgraded Electronic Arts to Neutral, saying the risk-reward on the stock appears to be "less compelling." The analyst is raising his price target to $100 from $92 and his FY20 EPS target to $4.36 from $4.02, but sees diminished potential from incremental drivers for FY20 given the "head fake" of early success for Apex Legends and indications of no recurrent revenue potential for Star Wars Jedi title. Handler also warns that Electronic Arts' mobile revenue could "decline double digits."
05/06/19
BUCK
05/06/19
NO CHANGE
Target $103
BUCK
Neutral
Electronic Arts selloff on Apex, China concerns 'unwarranted,' says Buckingham
Buckingham analyst Matthew Harrigan reiterates a Neutral rating and $103 price target on Electronic Arts. Nonetheless, the analyst would be opportunistic this week off what he feels was "unwarranted" negative price action on Friday from "very late" Apex Legends concerns and a likely reflexive China selloff on Monday, as well as uncertainty around earnings.
05/03/19
MKMP
05/03/19
DOWNGRADE
MKMP
Neutral
Electronic Arts downgraded to Neutral from Buy at MKM Partners
AVLR Avalara
$59.53

0.11 (0.19%)

04/11/19
NEED
04/11/19
INITIATION
NEED
Buy
Avalara initiated with a Buy at Needham
Needham analyst Scott Berg initiated Avalara with a Buy rating and $64 price target. The analyst believes the company "offers investors a well-positioned product suite in a large, complex, and fragmented TAM," or total available market. Berg sees Avalara's leverage becoming "more apparant" in the second half of the year as free cash flow turns positive, although he noted that he sees customer acquisition costs remaining high.
02/01/19
GSCO
02/01/19
INITIATION
Target $50
GSCO
Buy
Avalara resumed with a Buy at Goldman Sachs
Goldman Sachs analyst Christopher Merwin resumed coverage of Avalara with a Buy rating and $50 price target. The company provides mostly mid-market companies software solutions to pay their taxes more accurately and cost-effectively, Merwin tells investors in a research note. He sizes this global market opportunity at $10B, which leaves Avalara a "long runway for growth."
02/13/19
JPMS
02/13/19
NO CHANGE
Target $64
JPMS
Overweight
Avalara price target raised to $64 from $38 at JPMorgan
JPMorgan analyst Sterling Auty raised his price target for Avalara (AVLR) to $64 from $38 following the company's Q4 results. The December quarter is a "significant catalyst" for both the company and the stock as the positive impacts of the Supreme Court Wayfair (W) ruling has started to show "material benefits" to the business that will last for several years, Auty tells investors in a post-earnings research note. He keeps an Overweight rating on Avalara shares
02/13/19
KEYB
02/13/19
NO CHANGE
Target $54
KEYB
Overweight
Avalara price target raised to $54 from $48 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for Avalara to $54 from $48 on improving demand fundamentals. The analyst notes that the company closed out 2018 on a high note with growth accelerating to 33% year over year, a two-year high. The analyst reiterates an Overweight rating on the stock and says it remains one of the top cloud software ideas to own for 2019 based on a multi-year growth opportunity within sales tax compliance.
KGC Kinross Gold
$3.04

-0.03 (-0.98%)

09/06/18
FBCO
09/06/18
INITIATION
Target $4
FBCO
Neutral
Kinross Gold reinstated with a Neutral at Credit Suisse
Credit Suisse analyst Anita Soni reinstated Kinross Gold with a Neutral rating and a $4 price target. The analyst says she would need to see a sustained gold price recovery to become more positive on the stock.
10/10/18
LEHM
10/10/18
INITIATION
Target $4
LEHM
Overweight
Kinross Gold initiated with an Overweight at Barclays
Barclays analyst Matthew Murphy started Kinross Gold with an Overweight rating and $4 price target. The analyst rolled out coverage on the North American mining sector with a positive outlook. The current dollar-positive macro dynamic has taken its toll on mining equities, offering investors an attractive entry point to the sector, Murphy tells investors in a research note.
12/19/18
FBCO
12/19/18
DOWNGRADE
Target $3.25
FBCO
Underperform
Kinross Gold downgraded to Underperform from Neutral at Credit Suisse
Credit Suisse analyst Fahad Tariq downgraded Kinross Gold to Underperform with an unchanged price target of $3.25. The analyst cites Kinross' challenges to increase production, political risks, operational issues at Fort Knox and Round Mountain, and a higher cost profile versus peers for the downgrade.
08/20/18
RBCM
08/20/18
DOWNGRADE
Target $4.25
RBCM
Sector Perform
Kinross Gold downgraded to Sector Perform at RBC Capital on valuation
As reported earlier, RBC Capital analyst Stephen Walker downgraded Kinross Gold to Sector Perform from Outperform and lowered his price target to $4.25 from $5.00. The analyst notes that while positive catalysts remain, including the continued progress made in organic growth projects, the potential for expansion has been priced into the stock. Walker also points to the increased tax uncertainty and royalty payment outlook for the company's assets in Mauritania and Russia.
OUT Outfront Media
$24.00

0.03 (0.13%)

03/28/19
MSCO
03/28/19
NO CHANGE
MSCO
Local ad survey positive for Google and Facebook, says Morgan Stanley
Morgan Stanley analysts led by Benjamin Swinburne and Brian Nowak said the firm's annual local ad survey showed that expectations to grow marketing budgets remained robust. The survey results were positive for Google parent Alphabet (GOOGL) and Facebook (FB), as Google's search and Instagram stood out as having strong year-over-year increases in the number of small and medium businesses pointing to each as providing "the highest ROI," the analysts noted. Twitter (TWTR) and Yelp (YELP) both fell in terms of usage by local advertisers, the analysts also noted. Outdoor continues to slowly pick up budget share, according to the survey, which makes the analysts incrementally positive on Lamar Advertising (LAMR) and Outfront Media (OUT), they added.
03/28/19
OPCO
03/28/19
INITIATION
Target $30
OPCO
Outperform
Outfront Media initiated with an Outperform at Oppenheimer
Oppenheimer analyst Ian Zaffino started Outfront Media with an Outperform rating and $30 price target.
03/29/19
03/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Etsy (ETSY) initiated with a Perform at Oppenheimer. 2. Apellis (APLS) and uniQure (QURE) initiated with an Outperform at Baird. 3. BRT Apartments (BRT) initiated with a Buy at DA Davidson. 4. Lilis Energy (LLEX) initiated with an Equal Weight at Stephens. 5. Outfront Media (OUT) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/28/19
03/28/19
INITIATION
Target $30

Outperform
Outfront Media initiated with an Outperform at Oppenheimer
As previously reported, Oppenheimer analyst Ian Zaffino initiated Outfront Media with an Outperform rating and a price target of $30. The analyst cites the company's position as a "unique investment opportunity" in the "secularly growing out-of-home advertising industry". Zaffino also points to Outfront Media having "recently restored growth" and "successfully renewed its contract with the MTA". Furthermore, the analyst contends that the company "could be a consolidation target" after its fifth anniversary of REIT conversion in July as it "becomes significantly more tax-friendly."
QRVO Qorvo
$73.65

-0.67 (-0.90%)

04/12/19
MZHO
04/12/19
NO CHANGE
Target $335
MZHO
Buy
Broadcom price target raised to $335 from $305 at Mizuho
Mizuho analyst Vijay Rakesh raised his price target for Broadcom (AVGO) to $335 from $305 after taking a look at the handset landscape ahead of the March quarter results. Broadcom, Skyworks (SWKS) and Qorvo (QRVO) are well positioned with a stabilizing China handset market, Rakesh tells investors in a research note. The analyst says that while broader handset trends remain weak, with March quarter units down 15%-20% quarter-over-quarter and flattish into June, he sees less risk to estimates. Rakesh keeps a Buy rating on Broadcom and Neutral ratings on both Skyworks and Qorvo.
04/26/19
KEYB
04/26/19
DOWNGRADE
KEYB
Sector Weight
Qorvo downgraded to Sector Weight from Overweight at KeyBanc
04/26/19
KEYB
04/26/19
NO CHANGE
Target $350
KEYB
Overweight
Broadcom price target raised to $350 from $335 at KeyBanc
KeyBanc analyst John Vinh raised his price target for Broadcom (AVGO) to $350 from $335 and maintained an Overweight rating, telling investors in a research note that given recent supply chain feedback, he believes Broadcom has regained the mid-high band PAD share back from Qorvo (QRVO) in the 2019 iPhone.
04/26/19
KEYB
04/26/19
DOWNGRADE
KEYB
Sector Weight
Qorvo downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst John Vinh downgraded Qorvo (QRVO) to Sector Weight from Overweight, saying he had previously upgraded the stock as feedback from multiple supply chain partners indicated the company had been designed into the 2019 iPhone and was expected to gain share, as it relates to the mid/high-band PAD. However, Vinh tells investors in a research note that recent field work indicates that despite the design win, Qorvo has failed to be qualified and is likely to lose its share in the 2019 iPhone back to Broadcom (AVGO). As this was a key tenet of his Overweight thesis and he believes it puts forward estimates at risk, he downgraded the stock to Sector Weight.
JCOM j2 Global
$85.59

-1.41 (-1.62%)

04/22/19
DADA
04/22/19
NO CHANGE
Target $110
DADA
Buy
j2 Global price target raised to $110 from $100 at DA Davidson
DA Davidson analyst Rishi Jaluria raised his price target on j2 Global to $110 and kept his Buy rating after meeting with its CFO . Following the discussions, the analyst expects growth in the company's digital media business to come from "performance marketing and subscription", which will drive the management's M&A strategy to opportunities with "performance / subscription revenue stream". Jaluria adds that execution at Everyday Health, which J2 Global acquired last year, has "improved meaningfully, driven by new leadership and a change in philosophy around relationships with pharmaceutical companies."
04/03/19
SBSH
04/03/19
NO CHANGE
Target $95
SBSH
Buy
j2 Global price target raised to $95 from $86 at Citi
Citi analyst Nicholas Jones raised his price target for j2 Global to $95 from $86 after taking over coverage of the name from Walter Pritchard. He keeps a Neutral rating on j2. The company's growth prospects from cloud services will be "slow at best," balanced by moderate growth in digital media, Jones tells investors in a research note. However, j2's acquisition strategy "creates a floor" to the share price since the company has a track record of completing accretive deals, says the analyst. Nonetheless, the current economic climate of high valuations and a looming recession create "significant execution risk" in j2 Global's ability to find accretive opportunities, he adds.
12/20/18
WBLR
12/20/18
NO CHANGE
WBLR
Outperform
William Blair sees room for j2 Global to grow organically
After hosting investor meetings with management, William Blair analyst Jim Breen sees room for j2 Global to grow organically while admitting the majority of its growth will continue to come from acquisitions. The analyst views j2 as a "defensive stock with highly visible free cash flow and a stable dividend." He reiterates an Outperform rating on the shares.
10/19/18
WEDB
10/19/18
INITIATION
Target $95
WEDB
Outperform
j2 Global initiated with an Outperform at Wedbush
Wedbush analyst Daniel Ives initiated j2 Global with an Outperform rating and $95 price target, telling investors in a research note that he believes the company remains a "misunderstood story" by the Street as the company is still painted by many investors as a legacy fax player, serial M&A machine, and has low growth prospects/high margins that have largely played out over the past few years with headwinds ahead.
PAA Plains All American
$23.47

0.03 (0.13%)

02/06/19
TUDR
02/06/19
UPGRADE
TUDR
Buy
Plains All American upgraded to Buy from Hold at Tudor Pickering
01/02/19
GSCO
01/02/19
UPGRADE
Target $28
GSCO
Buy
Plains All American upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Jerren Holder upgraded Plains All American to Buy from Neutral and raised his price target to $28 from $27.
01/02/19
GSCO
01/02/19
NO CHANGE
Target $24
GSCO
Conviction Buy
Kinder Morgan remains top pick among midstream energy stocks, says Goldman Sachs
Goldman Sachs analysts Jerren Holder and Michael Lapides have a positive view of the Midstream energy stocks moving toward positive free cash flows, with Conviction Buy-rated Kinder Morgan (KMI) as their top pick. In a broader research note, the analysts also upgraded Plains All American (PAA) and Cheniere Energy (LNG) to Buy from Neutral and Semgroup (SEMG) and Sunoco (SUN) to Neutral from Sell. The analysts note that the "simplification thesis" in the sector continues to play out, volumes are growing, and "many new takeaway pipelines are coming online", even though the midstream stocks' performance has been lagging. Holder and Lapides believe that an inflection is ahead with more major projects coming online after a period of high capital spending.
02/05/19
EVER
02/05/19
INITIATION
Target $24
EVER
In Line
Plains All American initiated with an In Line at Evercore ISI
Evercore ISI analyst Durgesh Chopra initiated Plains All American with an In Line and $24 price target.
CRZO Carrizo Oil & Gas
$11.14

-0.56 (-4.79%)

04/09/19
COWN
04/09/19
INITIATION
Target $16
COWN
Market Perform
Carrizo Oil & Gas initiated with a Market Perform at Cowen
Cowen analyst Gabe Daoud, Jr. initiated Carrizo Oil & Gas with a Market Perform rating and $16 price target, saying Carrizo has transformed the portfolio through divestitures of non-core assets and two complementary acquisitions in the Delaware Basin. While the analyst tells investors in a research note that he likes the streamlined portfolio, he sees better opportunity for free cash flow among small-mid caps.
03/28/19
SPHN
03/28/19
INITIATION
Target $15
SPHN
Equal Weight
Carrizo Oil & Gas initiated with an Equal Weight at Stephens
Stephens analyst Drew Lipke initiated Carrizo Oil & Gas with an Equal Weight rating and a price target of $15. The analyst contends that the company will "perform in-line with peers" since the stock resides in the bottom third of his investment rank in terms of "organic oil growth, free cash flow, cash recycle ratio, ROCE, and valuation".
03/20/19
SOCO
03/20/19
UPGRADE
SOCO
Overweight
Carrizo Oil & Gas upgraded to Overweight from Equalweight at Capital One
Capital One upgraded Carrizo Oil & Gas to Overweight citing an increase in oil price deck assumptions.
04/23/19
IFSG
04/23/19
DOWNGRADE
IFSG
Market Perform
Carrizo Oil downgraded to Market Perform from Outperform at IFS Securities
PCTI PCTEL
$4.80

-0.13 (-2.64%)

08/09/18
LSCM
08/09/18
DOWNGRADE
LSCM
Hold
PCTEL downgraded to Hold from Buy at Lake Street
08/09/18
LSCM
08/09/18
DOWNGRADE
Target $6
LSCM
Hold
PCTEL downgraded to Hold with $6 target at Lake Street
Lake Street analyst Jaeson Schmidt downgraded PCTE to Hold from Buy and lowered his price target for the shares to $6 from $9. The company's Q3 outlook and the downward adjustment to full year guidance came in well below estimates as it is seeing meaningful headwinds in both of its business segments, Schmidt tells investors in a post-earnings research note. He finds it prudent to move to the sidelines until visibility improves. B. Riley FBR also downgraded PCTEL this morning.
08/09/18
RILY
08/09/18
DOWNGRADE
Target $4.5
RILY
Neutral
PCTEL downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Mike Crawford downgraded PCTEL to Neutral and lowered his price target for the shares to $4.50 from $8.50. The analyst sees the challenges that drove the reduced fiscal 2018 guidance persisting for the remainder of the year.
PZZA Papa John's
$51.37

-2.12 (-3.96%)

03/27/19
STFL
03/27/19
UPGRADE
Target $45
STFL
Hold
Papa John's upgraded to Hold from Sell at Stifel
Stifel analyst Chris O'Cull upgraded Papa John's International to Hold from Sell and raised his price target for the shares to $45 from $35. The analyst believes the company's turnaround has entered a phase where investors believe the worst is behind it "and are willing to accord the company a hall pass to see whether the sales plan can work." The more optimistic sentiment stems from the view that the new board of directors and new brand spokesperson Shaquille O'Neal can reverse the declining traffic and EBITDA trends, O'Cull tells investors in a research note titled "Sell Thesis Not a Slam Dunk; Investors Optimism Outweighing Fundamentals." The analyst remains concerned that low franchisee profits will require ongoing financial support from Papa John's and declining transactions will pressure commissary profits, but he believes investor optimism will likely outweigh these fundamental issues in the near-term.
03/27/19
03/27/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bed Bath & Beyond (BBBY) upgraded to Hold from Sell at Loop Capital with analyst Anthony Chukumba citing the recent proxy contest threat was posed by an activist hedge fund consortium amassing 5% of the company stock. 2. Papa John's (PZZA) upgraded to Hold from Sell at Stifel with analyst Chris O'Cull saying he believes the company's turnaround has entered a phase where investors believe the worst is behind it "and are willing to accord the company a hall pass to see whether the sales plan can work." 3. ON Semiconductor (ON) upgraded to Buy from Neutral at Goldman Sachs with analyst Mark Delaney saying while not immune to cyclical risks, ON has improved its exposure to secular opportunities in advanced driver assistance system image sensors, electric vehicles and the cloud. 4. Ralph Lauren (RL) upgraded to Outperform from Market Perform at Wells Fargo with analyst Ike Boruchow saying he views the company as a "rare standout" in his space, with increased visibility, running ahead of plan and with the potential for accelerating growth in the years ahead. 5. Lumentum (LITE) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/01/19
KERI
04/01/19
UPGRADE
KERI
Buy
Papa John's upgraded to Buy from Neutral at Kalinowski
02/27/19
SPHN
02/27/19
NO CHANGE
Target $55
SPHN
Overweight
Papa John's guidance better than feared, says Stephens
Stephens analyst Will Slabaugh said Papa John's February update was "somewhat encouraging" and that the company's guidance for FY19 was "better than feared." While he expects sales and margins to remain pressured throughout 2019, Slabaugh thinks market expectations are for a choppy recovery and the quarterly report "helped to keep the hope for $2.00 in EPS power alive," he tells investors. He maintains an Overweight rating and $55 price target on Papa John's shares.
TWO Two Harbors
$13.49

-0.11 (-0.81%)

07/24/18
DBAB
07/24/18
DOWNGRADE
Target $15.5
DBAB
Hold
Two Harbors downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst George Bahamondes downgraded Two Harbors Investment to Hold with an unchanged price target of $15.50. The analyst sees limited upside to current valuation levels with the shares trading at a premium to book value.
10/11/18
RAJA
10/11/18
INITIATION
RAJA
Outperform
Two Harbors initiated with an Outperform at Raymond James
08/10/18
LEHM
08/10/18
INITIATION
Target $17
LEHM
Overweight
Two Harbors reinstated with an Overweight at Barclays
Barclays analyst Mark DeVries reinstated coverage of Two Harbors Investment with an Overweight rating and $17 price target. The analyst views the company's Q2 results as "strong" and believes it has "strong ability" to manage book value.
03/26/19
NOMU
03/26/19
INITIATION
Target $14
NOMU
Neutral
Two Harbors initiated with a Neutral at Nomura Instinet
Nomura Instinet analyst Matthew Howlett started Two Harbors Investment with a Neutral rating and $18 price target. The analyst expects a "transitional" 2019 for the company as the CYS Investments acquisition is integrated. He also initiated coverage of the U.S. Mortgage REITs industry with a positive outlook. The environment for levered mortgage-based operating models is the best it's been since the Taper Tantrum, Howlett tells investors in a research note. He thinks the space is poised to attract interest from "yield-starved investors amid a low, range-bound interest rate environment and expected yield curve steepening."
JAZZ Jazz Pharmaceuticals
$128.74

-4.21 (-3.17%)

03/27/19
MZHO
03/27/19
NO CHANGE
Target $147
MZHO
Buy
Jazz Pharmaceuticals price target raised to $147 from $137 at Mizuho
Mizuho analyst Irina Koffler raised her price target for Jazz Pharmaceuticals to $147 from $137 to reflect the recent approval of Sunosi and last night's positive data in the Phase III trial of JZP-258. However, both of these events were largely expected, Koffler tells investors in a research note. She reiterates a Neutral rating on Jazz Pharmaceuticals.
03/19/19
RHCO
03/19/19
INITIATION
Target $163
RHCO
Buy
Jazz Pharmaceuticals initiated with a Buy at SunTrust
SunTrust analyst Gregg Gilbert started Jazz Pharmaceuticals with a Buy rating and $163 price target. The analyst expects the company to deliver "continued strong" revenue and earnings growth over the next several years. Further, he believes the market may not fully appreciate the size and durability of Jazz's largest product Xyrem.
03/19/19
WELS
03/19/19
NO CHANGE
Target $162
WELS
Outperform
Wells Fargo boosts Jazz target to $162, sees 'several' 2019 catalysts
Wells Fargo analyst David Maris raised his 2019 earnings per share estimate for Jazz Pharmaceuticals to $14.58 from $13.81 and 2020 estimate to $16.59 from $16.35 to reflect the company's guidance and annual report. Maris also increased his price target for the shares to $162 from $154. The analyst sees "several catalysts" in 2019 for the stock, including Xyrem launch for pediatric indication in late Q1, JZP-258 topline results for Phase 3 study in narcolepsy in Spring 2019, and the Solriamfetol FDA action date of March 20. Further, investors are looking for a deal to diversify away from Xyrem, and at the end of 2018, Jazz had cash and investments of $825M as well as undrawn capacity on its revolver of $1.6B, Maris tells investors in a research note. He maintains an Outperform rating on the shares.
03/21/19
WELS
03/21/19
NO CHANGE
Target $154
WELS
Outperform
Jazz appoval expected but still 'nice win' for shares, says Wells Fargo
Wells Fargo analyst David Maris says FDA approval of solriamfetol for excessive sleepiness associated with narcolepsy or obstructive sleep apnea, while largely expected by investors, is still a "nice win" for shares of Jazz Pharmaceuticals. The analyst estimates sales for solriamfetol of approximately $12M in 2019, ramping to $371M by 2023. Maris reiterates an Outperform rating on Jazz with a $154 price target. Additional potential catalysts for the stock include the Xyrem launch for pediatric indication in late Q1, JZP258 topline results for a Phase 3 study in narcolepsy in Spring 2019, and any update on the business development front, Maris tells investors in a research note. Jazz in midday trading is up 3%, or $3.45, to $137.02.
BECN Beacon Roofing
$37.63

-0.665 (-1.74%)

03/26/19
RHCO
03/26/19
NO CHANGE
Target $44
RHCO
Buy
Beacon Roofing weather-related disruptions should be limited, says SunTrust
SunTrust analyst Keith Hughes kept his Buy rating and $44 price target on Beacon Roofing after its negative Q2 pre-announcement yesterday. The analyst notes that while adverse weather factors reduced expectations, the outlook for the rest of the year suggests "minimal impact in future quarters". Hughes adds that roofing can actually see benefits from weather factors over the medium term as replacement demand rises, further stating that he is still assessing the latest "notable hail activity" most recently reported in Dallas.
03/26/19
JPMS
03/26/19
NO CHANGE
Target $36.5
JPMS
Neutral
Beacon Roofing Q2 miss negative for Owens Corning, says JPMorgan
Largely driven by the quarter's harsh weather, Beacon Roofing Supply (BECN) last night announced weaker than expected preliminary Q2 results, JPMorgan analyst Michael Rehaut tells investors in a research note. The preannouncement is a negative read-through for Owens Corning (OC), adds the analyst, who points out that his Q1 earnings per share estimate of 52c is already below the Street's 61c consensus. The analyst keeps a Neutral rating on Beacon Roofing with a $36.50 price target. The stock's valuation appropriately reflects the company's temporarily elevated leverage, recent challenges surrounding sales consistency and guidance, as well as upside potential over the next two years from the Allied integration, says Rehaut.
02/25/19
02/25/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Antares Pharma (ATRS) initiated with an Outperform at Cowen. 2. New Fortress Energy (NFE) initiated with a Buy at Citi and Stifel, an Overweight at Morgan Stanley, an Equal Weight at Barclays and an Oupterform at JMP Securities and Evercore ISI. 3. Aurora Cannabis (ACB), CannTrust Holdings (CNTTF), Flowr (FLWPF), Organigram (OGRMF) and The Green Organic Dutchman (TGODF) initiated with a Buy at Jefferies, Canopy Growth (CGC) and Emerald Health Therapeutics (EMHTF) initiated with a Hold, Cronos Group (CRON) and HEXO (HEXO) initiated with an Underperform. 4. Pulse Biosciences (PLSE) initiated with a Buy at H.C. Wainwright. 5. Beacon Roofing (BECN) initiated with a Neutral at Buckingham, while the firm initiated BMC Stock Holdings (BMCH) and TopBuild (BLD) with a Buy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/25/19
BUCK
02/25/19
INITIATION
BUCK
Neutral
Beacon Roofing initiated with a Neutral at Buckingham
Buckingham analyst Megan McGrath initiated Beacon Roofing with a Neutral and $38 price target citing uncertainties around the Allied integration and roofing demand. McGrath would like to see a positive turn in roofing or EBITDA margin improvement before turning more positive on shares.
TEUM Pareteum
$4.89

-0.29 (-5.60%)

04/26/19
OPCO
04/26/19
INITIATION
Target $7
OPCO
Outperform
Oppenheimer sees above 30% revenue growth for Pareteum, starts at Outperform
Oppenheimer analyst Timothy Horan last night initiated coverage of Pareteum with an Outperform rating and $7 price target. Pareteum has a software solution for enabling mobile virtual network operators, Internet of Things and applications on one network/cloud, Horan tells investors in a research note. The analyst believes the company can grow revenues above 30% for the next five years and ultimately double its 15% EBITDA margins. There are high barriers to entry to its integrated service, and most competitors have major channel conflicts, Horan contends. Further, Pareteum's backlog has seen "very strong growth" in the last few quarters, providing visibility on revenue growth, he adds.
02/19/19
NORL
02/19/19
NO CHANGE
Target $7.5
NORL
Outperform
Pareteum 'undervalued' following January wins, says Northland
Northland analyst Michael Latimore notes that Pareteum announced on Friday 12 wins in the month of January. The analyst likes that the company is winning more U.S.-based customers, and argues that the wins and associated increase in backlog give him more confidence in his estimates. Overall, Latimore believes Pareteum is undervalued, trading at only 3.76 times his FY19 revenue estimates and 2.93 times FY20. He reiterates an Outperform rating and $7.50 price target on the shares.
04/25/19
OPCO
04/25/19
INITIATION
Target $7
OPCO
Outperform
Pareteum initiated with an Outperform at Oppenheimer
Oppenheimer analyst Timothy Horan started Pareteum with an Outperform rating and $7 price target.
02/15/19
NORL
02/15/19
NO CHANGE
Target $7.5
NORL
Outperform
Pareteum backlog announcement increases Northland confidence in estimates
After Pareteum announced continued increases in its 3-year backlog yesterday, Northland analyst Michael Latimore said the company's announcement gives him more confidence in his estimates. The analyst, who noted that the recently complete iPass acquisition gives Pareteum 100 more people to help deploy backlog, keeps an Outperform rating and $7.50 price target on the stock.
INGN Inogen
$90.97

-5.13 (-5.34%)

04/23/19
PIPR
04/23/19
NO CHANGE
PIPR
Piper sees Q1 revenue upside for Inogen, Teleflex, Align Technology
Piper Jaffray analyst Matt O'Brien says his deep dive into the MedTech companies exploring the direct-to-consumer sales channel came up "most compelling" for Inogen (INGN), Teleflex (TFX) and Align Technology (ALGN). Website traffic at these companies is at or near three-year highs and historical trends suggest a high likelihood of revenue upside in Q1, O'Brien tells investors in a research note. The analyst also found DexCom's (DXCM) website traffic to be at three-year highs.
04/21/19
PIPR
04/21/19
NO CHANGE
Target $185
PIPR
Overweight
Oxygen survey confirms TAM, supports Inogen bull thesis, says Piper Jaffray
Piper Jaffray analyst JP McKim believes his oxygen survey debunks a lot of the bearish arguments around the Medicare Claims data and supports his long-term Inogen bull thesis. That said, the survey did not give him a ton of confidence in near-term BTB results. While the analyst does not get the sense Q1 is going to be the snap back quarter like he expects Q2 to be, he argues that with the stock at $79, a lot of that is already reflected in the share price. Finally, as investors have been solely relying on the Medicare claims data for market sizing, McKim believes this survey provides another data point to confirm the market is large, still growing, and shifting to POCs. He reiterates an Overweight rating and $185 price target on the shares.
04/03/19
PIPR
04/03/19
NO CHANGE
Target $185
PIPR
Overweight
Inogen price increase an unexpected positive, says Piper Jaffray
Piper Jaffray analyst JP McKim notes that the Inogen G5 officially was released to customers via the DTC channel and will be made available BTB domestic and BTB international in the coming months through a controlled roll out. The analyst says that the company can now market the G5 as market leading on all important categories like weight, flow rate, battery life and sound and will therefore go for a premium price. The company is increasing its minimum advertised price to $2,995 for the G5, up from $2,300 for G4/G3, he points out, adding that he believes this price increase was not expected by investors and sees it as a positive as people adjust their models. McKim reiterates an Overweight rating and $185 price target on the shares.
03/11/19
PIPR
03/11/19
NO CHANGE
Target $185
PIPR
Overweight
Inogen recent share selloff 'way overdone,' says Piper Jaffray
After visiting the company's headquarters and meeting with its CFO, Piper Jaffray analyst JP McKim says the recent pullback in shares of Inogen is "way overdone." While the analyst does not expect "anything heroic in terms of a massive bounce back" in Q1 business-to-business sales, he points out that management did seem more open to a stock buyback program than they have in previous meetings. In 10 years, there will not be patients wheeling around oxygen tanks and Inogen remains the best way to play this "thematic shift," McKim tells investors in a research note. He keeps an Overweight rating on the shares with a $185 price target. The stock closed Friday down $3.28 to $93.95.
TWOU 2U
$59.99

-2.36 (-3.79%)

03/06/19
BREN
03/06/19
INITIATION
Target $102
BREN
Buy
2U initiated with a Buy at Berenberg
Berenberg initiated 2U with a Buy and $102 price target.
02/26/19
BMOC
02/26/19
NO CHANGE
Target $83
BMOC
Outperform
2U price target raised to $83 from $72 at BMO Capital
BMO Capital analyst Jeffrey Silber raised his price target on 2U to $83 and kept his Outperform rating after its in-line Q4 results. The analyst cites the company's marketing investments to attract more students and fill capacity along with its latest "KeyPath partnership to offer an institutional suite of services". Silver believes that 2U can sustain its "solid" long-term growth trajectory.
04/09/19
DADA
04/09/19
NO CHANGE
Target $88
DADA
Buy
DA Davidson positive on 2U acquisition of Trilogy Education
DA Davidson analyst Rishi Jaluria kept his Buy rating and $88 price target on 2U after its announced deal to buy Trilogy Education for $750M in cash and stock. The analyst is positive on the acquisition, which he believes "creates another lever of growth in corporate learning" and expands its university footprint while also offering "meaningful cross-sell opportunities." Jaluria also maintains a constructive view on the stock thanks to the company's "leadership position in online program management, attractive long-term financial model, and multiple growth drivers."
02/26/19
BRRR
02/26/19
NO CHANGE
Target $90
BRRR
Outperform
2U price target raised to $90 from $75 at Barrington
Barrington analyst Alexander Paris raised his price target for 2U to $90 after the company's Q4 results topped expectations. Further, 2U's projected growth rate of 33% in 2019 is much higher than the average of 15% for the Education Tech peer group and 22% for the high-growth Software-as-a-Service peer group, Paris tells investors in a post-earnings research note. The analyst reiterates an Outperform rating on 2U.
SUPN Supernus
$36.98

-1.22 (-3.19%)

01/28/19
RILY
01/28/19
NO CHANGE
Target $65
RILY
Buy
Supernus added to Alpha Generator list at B. Riley FBR
B. Riley FBR analyst David Buck added Supernus Pharmaceuticals to his firm's Alpha Generator list and reiterates a Buy rating on the shares with a $65 price target. He expects continued growth for Trokendi XR despite new entrants in the migraine category.
04/11/19
JEFF
04/11/19
NO CHANGE
Target $58
JEFF
Buy
Supernus ADHD drug can reach $500M in sales, says Jefferies
Supernus Pharmaceuticals' SPN-812 has generated promising efficacy and safety data and several features may differentiate it from market leader Straterra, Jefferies analyst David Steinberg tells investors in a research note. The analyst estimates sales could reach $500M or more over time post a projected 2020 launch. The overall adult attention-deficit/hyperactivity disorder market remains "very large" and within the category, non-stimulant drugs represent a "major opportunity" and the two FDA approved drugs available are "suboptimal," Steinberg contends. He keeps a Buy rating on Supernus with a $58 price target.
01/31/19
01/31/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. At Home Group (HOME) initiated with a Hold at Gordon Haskett. 2. Teladoc (TDOC) initiated with a Buy at Berenberg. 3. Intercept (ICPT) initiated with an Outperform at Credit Suisse. 4. Recro Pharma (REPH), BioDelivery Sciences (BDSI), and Supernus (SUPN) were assumed with a Buy at Janney Montgomery Scott. 5. Green Thumb Industries (GTBIF) initiated with a Buy at Benchmark. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/31/19
JANY
01/31/19
INITIATION
Target $55
JANY
Buy
Supernus assumed with a Buy at Janney Montgomery Scott
Janney Montgomery Scott analyst Esther Hong assumed coverage of Supernus with a Buy rating and $55 fair value estimate.
DDD 3D Systems
$10.59

-0.4 (-3.64%)

04/22/19
CHLM
04/22/19
INITIATION
Target $12
CHLM
Hold
3D Systems initiated with a Hold at Craig-Hallum
Craig-Hallum analyst Greg Palm started coverage of 3D Systems with a Hold rating and a $12 price target. The analyst likes the company's positioning in healthcare especially, but "erratic results" make this "a show me story."
03/01/19
JPMS
03/01/19
NO CHANGE
Target $8
JPMS
Underweight
3D Systems price target lowered to $8 from $10 at JPMorgan
JPMorgan analyst Paul Coster lowered his price target for 3D Systems to $8 following the company's Q4 results and keeps an Underweight rating on the shares. Though the company looks for profitable growth in 2019, progress will be "heavily" backend-loaded, owing to slower enterprise sales in the seasonally weak Q1, and a continued delay in anticipated materials ramp, Coster tells investors in a research note. Further, while printer shipment growth continues to be strong, average selling prices are declining, adds the analyst.
04/01/19
JPMS
04/01/19
NO CHANGE
JPMS
Underweight
3D Systems, Stratasys struggling to defend market share, says JPMorgan
This year's Wohlers Report continues to depict a competitive 3D industry whose growth is increasingly fueled by end-parts manufacturing and functional prototyping, JPMorgan analyst Paul Coster tells investors in a research note. 3D Systems (DDD) and Stratasys (SSYS) are struggling to defend market share in a growing 3D production market, owing to stiffening competition from bigger companies that are entering the industrial system space, says the analyst. He keeps an Underweight rating on both names. Coster believes the "paucity of pure-play investable ideas continues to buoy valuation multiples beyond the level justified by actual growth prospects."
04/30/19
PIPR
04/30/19
NO CHANGE
PIPR
3D printing demand trends improving into Q1 results, says Piper Jaffray
Piper Jaffray analyst Troy Jensen says his Q1 reseller survey indicates 3D printing demand was mostly in line with expectations for the March quarter. System demand down-ticked quarter-over-quarter, but was up "nicely" on a year-over-year basis, while material demand was modestly above plan and service bureau demand "bounced back sharply following a challenging Q4," Jensen tells investors in a research note. He believes underlying demand trends are improving for the 3D printing industry and anticipates accelerating growth as the industry moves through 2019 and beyond. Stratasys' (SSYS) new product introductions and production emphasis will see growth pick up in the second half of 2019, contends the analyst. And 3D Systems (DDD) should also benefit from production application demand improving and other new product launches, Jensen adds. He reiterates Overweight ratings on both stocks.
NVTA Invitae
$23.80

-1.21 (-4.84%)

04/23/19
BNCH
04/23/19
NO CHANGE
BNCH
UnitedHealth preferred lab launch a long-term plus for Invitae, says Benchmark
Benchmark analyst Bruce Jackson noted that UnitedHealthcare (UNH) plans to launch a Preferred Laboratory Network to include Invitae (NVTA), which he views as a long-term positive for the latter and "another building block for Invitae's strategy to make genetic testing more widely available and more easily reimbursed." Other labs named to the preferred network include LabCorp (LH), Quest Diagnostics (DGX), and BioReference and GeneDx, which are both part of Opko (OPK), the analyst noted. UnitedHealthcare's current network includes NeoGenomics (NEO) and he doesn't anticipate any impact to NeoGenomics from the preferred network launch, added Jackson.
03/04/19
CHDN
03/04/19
INITIATION
Target $29
CHDN
Buy
Invitae initiated with a Buy at Chardan
Chardan analyst Steven Wardell initiated Invitae with a Buy and $29 price target. Wardell said Invitae is the cost and quality leader in the genetic testing market with a centralized testing and data strategy that positions the company to compete in this large, and attractive market. The analyst expects strong topline growth over the next three years and likes management's ability to execute and their confidence on where the sector is going and their place in it. He believes shares are mispriced versus peers given it is a growth leader among high-growth digital health companies.
03/04/19
03/04/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. MannKind (MNKD) initiated with an Outperform at SVB Leerink. 2. Invitae (NVTA) initiated with a Buy at Chardan. 3. Immunomedics (IMMU) initiated with a Buy at H.C. Wainwright. 4. Canopy Growth (CGC) initiated with a Neutral at Melius Research. 5. Alector (ALEC) initiated with an Overweight at Morgan Stanley and Barclays, an Outperform at SVB Leerink and Cowen, as well as a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/08/19
OPCO
04/08/19
NO CHANGE
Target $30
OPCO
Outperform
Invitae price target raised to $30 from $21 at Oppenheimer
Oppenheimer analyst Kevin DeGeeter raised his price target for Invitae to $30 from $21 based on improved long-term competitive positioning for the company's patient-initiated testing given data presented at the ACMG meeting demonstrating poor performance for a leading DTC genetic test and potential consolidation in DTC market as industry matures and economies of scale, quality/clinical data and regulatory oversight drive market share. The analyst reiterates an Outperform rating on the shares.
LTHM Livent
$10.73

-0.24 (-2.19%)

04/15/19
SBSH
04/15/19
DOWNGRADE
SBSH
Neutral
Livent downgraded to Neutral from Buy at Citi
Citi analyst P.J. Juvekar downgraded Livent to Neutral from Buy with a $13 price target.
03/03/19
LOOP
03/03/19
NO CHANGE
Target $101
LOOP
Buy
FMC Corporation price target lowered to $101 from $118 at Loop Capital
Loop Capital analyst Chris Kapsch lowered his price target for FMC Corporation (FMC) to $101 from $118 to reflect the spin of Livent (LTHM). The analyst reiterates a Buy rating on FMC Corporation's shares.
03/01/19
LOOP
03/01/19
NO CHANGE
Target $18
LOOP
Buy
Livent long term growth story intact, says Loop Capital
Loop Capital analyst Chris Kapsch warns that Livent shares could experience some volatility in the next couple of days as the "remaining 85% of former parent ownership will be distributed to shareholders in a tax-free spin". The analyst is also keeping his Buy rating and $18 price target on the stock, saying Livent's loner-term growth story is not broken and that he would take advantage of any pullback.
04/15/19
SBSH
04/15/19
DOWNGRADE
Target $13
SBSH
Neutral
Citi sees lithium as 'buyer's market,' downgrades Livent to Neutral from Buy
Citi analyst P.J. Juvekar downgraded Livent (LTHM) to Neutral from Buy and lowered his price target for the shares to $13 from $15. The analyst also reduced his price target for Neutral-rated Albemarle (ALB) to $88 from $92. Following a site visit to the Salar de Atacama and meetings with SQM's (SQM) CFO, Juvekar gets the sense that the lithium market "has become a buyer's market." Chinese buyers seem to have become more aggressive and China's new energy vehicle subsidy cuts may weigh on the market beginning in the second half of 2019, the analyst tells investors in a research note. While Albemarle and Livent's volumes are secured under multi-year terms, pricing for future volumes could come under pressure as new conversion capacity ramps up in 2019-2020, contends Juvekar. He reduced his valuation multiples for both stocks as "competition in the lithium market increases."
HCLP Hi-Crush Partners
$3.60

-0.04 (-1.10%)

01/09/19
JEFF
01/09/19
NO CHANGE
Target $2.5
JEFF
Underperform
Jefferies sees more downside for Hi-Crush Partners, Smart Sand
Investor expectations for normalized frac sand earnings power are now more reasonable, but lofty valuations suggest stocks are still pricing in solid medium term recovery, "which is hardly a given," Jefferies analyst Saurabh Pant tells investors in a research note titled "Fractured Sand, Squeezed Out Equity Value." Further, high debt "continues to crowd out equity value" and limited free cash flow improvement suggests more downside for frac sand pure-plays Hi-Crush Partners (HCLP) and Smart Sand (SND), adds the analyst. He views U.S. Silica (SLCA) as "more defensive" and finds it "interesting" on free cash flow yield, but says the stock lacks positive catalysts. Pant sees "continued oversupply, weak earnings and thus further downside to equity" values. The analyst lowered his price target for Hold-rated Covia (CVIA) to $4 from $7, for Underperform-rated Hi-Crush to $2.50 from $5, for Underperform-rated Smart Sand to $2 from $2.50 and for Hold-rated U.S. Silica to $13 from $16
04/02/19
JEFF
04/02/19
NO CHANGE
Target $18
JEFF
Hold
Jefferies stays negative on frac sand despite raising price targets
The recent Northern White Sand spot pricing strength should reverse in the second half of 2019 as exploration and production spending edges lower in back half of the year, logistics bottlenecks ease, and more in-basin mines start up, Jefferies analyst Saurabh Pant tells investors in a research note. He sees total effective utilization remaining at ~50% and earnings "remaining flattish" into 2020. As such, he stays negative on frac sand and reiterates Underperform ratings on pure plays Hi-Crush Partners (HCLP) and Smart Sand (SND) as well as Hold ratings on the more diversified U.S. Silica Holdings (SLCA) and Covia (CVIA). "We watch for active short opportunities to emerge through" Q2, says Pant. The analyst, however, raised his price target for Covia to $6 from $4, for Hi-Crush to $3.50 from $2.50, for Smart Sand to $3.50 from $2, and for U.S. Silica to $18 from $15.
01/30/19
OTRG
01/30/19
UPGRADE
OTRG
Mixed
North American Frac Sand Market raised to Mixed from Negative at OTR Global
OTR Global raised its rating on the North American Frac Sand Market to Mixed from Neutral following checks that indicate demand and spot prices are slowly stabilizing in January following a drop in Q4.
01/08/19
RILY
01/08/19
DOWNGRADE
Target $6.5
RILY
Neutral
Hi-Crush Partners downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Lucas Pipes downgraded Hi-Crush Partners to Neutral citing yesterday's "bearish" Q4 update. The analyst cut his price target for the shares to $6.50 from $10.
TRIP TripAdvisor
$54.92

-1.14 (-2.03%)

03/06/19
COWN
03/06/19
DOWNGRADE
Target $40
COWN
Underperform
TripAdvisor downgraded to Underperform on weak 2019 start at Cowen
As reported previously, Cowen analyst Kevin Kopelman downgraded TripAdvisor (TRIP) to Underperform from Market Perform. The analyst cited a weak start to 2019, expectations for weaker usage, and worries about younger age demos using Google (GOOG). He expects profit growth to slow to single digits by 2020 and thinks the stock's multiple should now be more in line with peers. Kopelman lowered his price target to $40 from $50 on TripAdvisor shares.
05/03/19
DBAB
05/03/19
UPGRADE
Target $65
DBAB
Buy
TripAdvisor upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded TripAdvisor to Buy from Hold with a $65 price target.
04/12/19
RHCO
04/12/19
NO CHANGE
Target $62
RHCO
Hold
TripAdvisor price target lowered to $62 from $66 at SunTrust
SunTrust analyst Naved Khan lowered his price target on TripAdvisor to $60 and kept his Hold rating, reflecting an "incremental impact" from an adverse FX and macro environment even though he still sees double-digit EBITDA growth this year. The analyst also believes that growth in the core Hotel business is likely to remain pressured by the company's advertising cuts in the near term, but he expects TripAdvisor fundamentals to stabilize on better monetization and product enhancements.
03/06/19
03/06/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. TripAdvisor (TRIP) downgraded to Underperform from Market Perform at Cowen with analyst Kevin Kopelman citing a weak start to 2019, expectations for weaker usage, and worries about younger age demos using Google (GOOG). 2. Teva (TEVA) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger citing his belief that the stock's premium valuation largely prices in expectations for upside in the coming quarters due to cost cutting and conservative Copaxone guidance. 3. VMware (VMW) downgraded to Sell from Neutral at Goldman Sachs, while Pivotal Software (PVTL) was downgraded to Neutral from Buy. 4. Ormat Technologies (ORA) downgraded to Neutral from Overweight at JPMorgan with the firm's analyst citing a lack of catalysts for share appreciation in 2019. 5. CSX (CSX) downgraded to Hold from Buy at Stifel with analyst Michael Baudendistel saying he no longer sees a solid reason why shares should outperform the market in the next twelve months. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
OPK Opko Health
$2.36

-0.12 (-4.84%)

03/15/19
JEFF
03/15/19
UPGRADE
Target $5
JEFF
Buy
Opko Health assumed with a Buy from Hold at Jefferies
Jefferies analyst Maury Raycroft assumed coverage of Opko Health and upgraded the shares to Buy from Hold. The analyst raised his price target for the stock to $5 from $4. The company had a rough 2018, and though some headwinds may still be ahead, the "terrain gets a little smoother and more interesting in 2019." Raycroft tells investors in a research note. He sees the oxyntomodulin Phase IIb data by end of March as the next catalyst and does not believe the Street is focused on this program. Further, Rayaldee dialysis data by the end of 2019 "could put the drug on a different level commercially," says Raycroft.
02/28/19
BRRR
02/28/19
NO CHANGE
Target $5
BRRR
Outperform
Opko Health risk/reward still favors investment, says Barrington
Barrington analyst Michael Petusky lowered his price target for Opko Health to $5 from $7 after the company's Q4 revenue missed his estimate and Q1 guidance came in less than expected. The analyst, however, maintains an Outperform rating on the shares. He believes the risk/reward still favors investment.
02/01/19
BRRR
02/01/19
NO CHANGE
Target $7
BRRR
Outperform
Barrington lowers Opko revenue estimate by $15M for 4Kscore news
Novitas Solutions, Opko Health's Medicare Administrative Contractor, has followed through on its initial non-coverage determination for 4Kscore issued in May 2018 and has communicated its intention to stop reimbursing for the test as of March 20, 2019, Barrington analyst Michael Petusky tells investors in a research note. Opko has spent the past eight months trying to communicate the value of 4Kscore to Novitas "and has clearly fallen short in this effort," says Petusky. The analyst, who "highly" doubts this decision will be reversed "any time soon," believes in the value of the test based on experts he's heard weigh in on the issue. The news is very disappointing, but Opko will continue to have some near-term opportunity to continue to educate commercial payors and perhaps get some "wins," Petusky writes. He reduced his annual revenue estimate for 4Kscore contribution by about $15M and keeps an Outperform rating on Opko Health with a $7 price target.
S Sprint
$5.78

0.04 (0.70%)

05/07/19
05/07/19
NO CHANGE

T-Mobile, Sprint select Henrietta, NY for T-Mobile Customer Experience Center
T-Mobile US (TMUS) and Sprint Corporation (S) announced that they have selected Henrietta, New York, as the location for their previously announced Greater Rochester area Customer Experience Center, subject to the close of their merger to become the New T-Mobile. At full operation, the New T-Mobile CEC facility in Henrietta will directly employ more than 1,000 workers in the community and indirectly produce another 500 to 600 jobs. The new CEC jobs will feature great wages and benefits and will make the New T-Mobile one of the region's top 20 largest employers. The Henrietta CEC will support the expanded deployment of T-Mobile's innovative Team of Experts service model, which provides customers direct personal access to a dedicated team of specialists when they call or message for assistance. Specialists based in the Henrietta CEC will serve a large portion of the Northeast, including New York State. T-Mobile is not seeking any economic incentives related to this facility. In selecting the Greater Rochester area, T-Mobile engaged the Center for Governmental Research, an independent nonprofit consultancy, to conduct a thorough assessment of the economic and fiscal impact of a proposed Henrietta CEC on the Greater Rochester region. CGR found that the new development would likely generate significant economic momentum for the Greater Rochester area. According to CGR's analysis the region will see the following benefits: Spillover effects of New T-Mobile's investment will generate 500 to 600 jobs in addition to the up to approximately 1300 direct CEC employees within the region. CEC employee payroll will range from $22.1 to $26.0 million and will generate a combined income/sales tax of $1.5 to $1.8 million. Construction-phase investment will produce 200 direct and 30 spillover jobs with a total combined payroll of $13.0 million. Compensation and spending at the fully operational CEC will include $2.6 to $3.2 million in income tax and $1.7 to $2.0 million in combined state and local sales tax. The completion of the combination remains subject to regulatory approvals and certain other customary closing conditions. Federal regulatory approval is expected in the first half of 2019.
04/30/19
KEYB
04/30/19
NO CHANGE
Target $215
KEYB
Overweight
SBA Communications price target raised to $215 from $195 at KeyBanc
KeyBanc analyst Brandon Nispel raised his price target for SBA Communications to $215 from $195 as he continues to expect accelerating organic growth in its domestic business in 2019 versus 2018 and sees further potential for acceleration in 2020 versus 2019 if the T-Mobile (TMUS)/Sprint (S) merger is approved. The analyst also believes valuations can continue to trend higher given strong underlying growth in the business and his view that guidance could continue to be raised in 2019. He reiterates an Overweight rating on SBA Communications shares.
04/29/19
RAJA
04/29/19
DOWNGRADE
RAJA
Market Perform
Sprint downgraded to Market Perform from Outperform at Raymond James
04/26/19
KEYB
04/26/19
NO CHANGE
Target $88
KEYB
Overweight
T-Mobile price target raised to $88 from $76 at KeyBanc
KeyBanc analyst Brandon Nispel raised his price target for T-Mobile (TMUS) to $88 from $76, saying he believes that "with or without" Sprint (S), T-Mobile's fundamentals and market position are extremely strong relative to its valuation and he would be aggressively buying shares. Nispel tells investors in a research note that he sees potential for T-Mobile to beat subscriber expectations in 2019, beat adjusted EBITDA expectations and believes the skeptics view on lower than expected ARPU and gross additions as "wrong." He backs an Overweight rating on the shares.
WING Wingstop
$76.17

0.01 (0.01%)

04/02/19
GUGG
04/02/19
DOWNGRADE
GUGG
Neutral
Wingstop downgraded to Neutral from Buy at Guggenheim
04/02/19
GUGG
04/02/19
DOWNGRADE
Target $72
GUGG
Neutral
Guggenheim downgrades Wingstop to Neutral, cuts target to $72
Guggenheim analyst Matthew DiFrisco downgraded Wingstop to Neutral from Buy and lowered his price target for the shares to $72 from $80. The analyst sees increased risk to moderating new store growth and the current valuation multiple. Rising wing costs, coupled with a 100 basis point increase to advertising contributions, represent headwinds to Wingstop's 10% franchise development goal, DiFrisco tells investors in a research note. The analyst reduced his below-consensus EBITDA and earnings estimates to reflect lower company store revenue and profit. However, he raised his Q1 same-store-sales estimate from 3% to 3.5% on account of strong wing conversations across Instagram and elevated marketing.
04/02/19
04/02/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Sell from Neutral at UBS with analyst Michael Leuchten saying last week's oncology deal with Japan's Daiichi Sankyo suggests limited cash generation in the near term and is a sign of slow margin recovery. 2. Alcoa (AA) downgraded to Neutral from Outperform at Credit Suisse with analyst Curt Woodworth saying China is set to accelerate supply growth over the next several years as capacity swaps convert to new smelters and provincial focus pivots to growth model. 3. Pacific Biosciences (PACB) downgraded to Equal Weight from Overweight at Stephens with analyst Drew Jones saying the shares are within 10% of the looming purchase price by Illumina (ILMN). 4. Wingstop (WING) downgraded to Neutral from Buy at Guggenheim with analyst Matthew DiFrisco saying he sees increased risk to moderating new store growth and the current valuation multiple. 5. DowDuPont (DWDP) downgraded to Neutral from Buy at Citi and BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/06/19
WELS
05/06/19
NO CHANGE
Target $84
WELS
Outperform
Wingstop price target raised to $84 from $76 at Wells Fargo
Wells Fargo analyst Jon Tower raised his price target Wingstop to $84 from $76 ahead of quarterly results. The analyst thinks there's upside to Street same-store sales estimates on the back of increased ad spending year over year and the expansion of delivery, but notes that the move in wing prices in Q1 may cap flow-through in the quarter. Tower reiterates an Outperform rating on the shares.
LYFT Lyft
$59.38

-0.92 (-1.53%)

05/03/19
COWN
05/03/19
NO CHANGE
Target $77
COWN
Outperform
Cowen sees strong results coming from Lyft in first public report
Cowen analyst John Blackledge said he expects "strong results" from Lyft in its first earnings report since coming public, which is due on next Tuesday, May 7. He forecasts active riders to have increased 40% year-over-year to 19.7M and sees revenue at $745M, which would be up 88% year-over-year compared to the 94% growth rate from the company's fourth quarter. Blackledge forecasts an adjusted EBITDA loss of $243.4M, which compares to a consensus estimate of a loss of $282.4M. He maintains an Outperform rating and $77 price target on Lyft shares.
05/03/19
05/03/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Lyft (LYFT) initiated with an Underweight at Atlantic Equities. 2. Contura Energy (CTRA) initiated with a Buy at Seaport Global. 3. Uber (UBER) initiated with a Neutral at Atlantic Equities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/03/19
ATLE
05/03/19
INITIATION
Target $55
ATLE
Neutral
Atlantic starts Uber with Neutral rating despite preferring over Lyft
Atlantic Equities analyst James Cordwell initiated coverage of Uber (UBER) with a Neutral rating and $55 price target ahead of the company's initial public offering. The analyst this morning also initiated coverage of Lyft (LYFT) with an Underweight rating and $50 price target. Transportation-as-a-service addresses a large market opportunity, says the analyst, whose analysis shows that scale enables superior returns and a clearer path to profitability. Given the benefits of scale, Cordwell prefers Uber to Lyft, due to the company's "market-leading ridehailing position augmented by the fast-growing Eats business and freight brokerage opportunity." The analyst's year-end 2019 price target of $55 for Uber implies 0.9 times fiscal 2020 gross bookings, which he notes is similar to the historical average multiple of Amazon's (AMZN) e-commerce business.
05/03/19
ATLE
05/03/19
INITIATION
Target $50
ATLE
Underweight
Lyft initiated with an Underweight at Atlantic Equities
Atlantic Equities analyst James Cordwell initiated Lyft (LYFT) with an Underweight rating and $50 price target. In a research note to investors, Cordwell, who also initiated Uber (UBER) with a Neutral rating, says he prefers Uber over Lyft, as U.S. share losses and deteriorating unit economics leave him unable to be constructive on Lyft currently, especially given ongoing capital inflows into the sector will likely ensure competition remains intense.

TODAY'S FREE FLY STORIES

TEVA

Teva

$10.86

-0.18 (-1.63%)

12:11
05/26/19
05/26
12:11
05/26/19
12:11
Hot Stocks
Teva reaches $85M agreement with State of Oklahoma »

Teva Pharmaceuticals USA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESLT

Elbit Systems

$141.85

1.33 (0.95%)

12:08
05/26/19
05/26
12:08
05/26/19
12:08
Hot Stocks
Elbit Systems awarded $127M contract to provide tactical radio system »

Elbit Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

ADM

Archer Daniels

$39.17

-0.03 (-0.08%)

12:05
05/26/19
05/26
12:05
05/26/19
12:05
Hot Stocks
Archer Daniels expands recall of Baker's Corner All Purpose Flour 5lb bags »

ADM Milling is recalling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

JCP

J.C. Penney

$0.93

0.022 (2.42%)

, DDS

Dillard's

$56.57

0.25 (0.44%)

13:29
05/25/19
05/25
13:29
05/25/19
13:29
Periodicals
Target stock triumphs in brutal week for retail, Barron's says »

Earnings season has been…

JCP

J.C. Penney

$0.93

0.022 (2.42%)

DDS

Dillard's

$56.57

0.25 (0.44%)

KSS

Kohl's

$51.11

-0.04 (-0.08%)

JWN

Nordstrom

$33.50

-0.31 (-0.92%)

M

Macy's

$21.00

-0.27 (-1.27%)

TGT

Target

$81.57

2.17 (2.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

JPM

JPMorgan

$109.78

1.14 (1.05%)

, AKZOY

AkzoNobel

$0.00

(0.00%)

13:24
05/25/19
05/25
13:24
05/25/19
13:24
Periodicals
Microsoft, JPMorgan among dividend champions, Barron's says »

Among the companies that…

JPM

JPMorgan

$109.78

1.14 (1.05%)

AKZOY

AkzoNobel

$0.00

(0.00%)

XOM

Exxon Mobil

$74.12

0.33 (0.45%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

CMWAY

Commonwealth Bank of Australia

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

T

AT&T

$32.29

0.15 (0.47%)

RDS.A

Royal Dutch Shell

$63.29

0.84 (1.35%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$87.49

3.03 (3.59%)

BHP

BHP Group

$52.47

1.18 (2.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 16

    Jul

  • 24

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

GM

General Motors

$35.13

0.01 (0.03%)

, TSLA

Tesla

$190.80

-4.7 (-2.40%)

13:19
05/25/19
05/25
13:19
05/25/19
13:19
Periodicals
Tesla stock in trouble, Barron's says »

Tesla (TSLA) stock is the…

GM

General Motors

$35.13

0.01 (0.03%)

TSLA

Tesla

$190.80

-4.7 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 01

    Aug

RNLSY

Renault

$0.00

(0.00%)

13:14
05/25/19
05/25
13:14
05/25/19
13:14
Periodicals
Renault stock may rally, Barron's says »

Shares of French auto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

, DWDP

DowDuPont

$31.10

0.16 (0.52%)

13:11
05/25/19
05/25
13:11
05/25/19
13:11
Periodicals
DowDuPont spinoff a new agriculture stock, FMC safer bet, Barron's says »

The crop-protection and…

FMC

FMC Corporation

$70.88

-0.47 (-0.66%)

DWDP

DowDuPont

$31.10

0.16 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 25

    Jun

MGM

MGM Resorts

$25.55

0.19 (0.75%)

13:03
05/25/19
05/25
13:03
05/25/19
13:03
Periodicals
MGM Resorts looks like an attractive gambling play, Barron's says »

MGM Resorts (MGM) stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PYPL

PayPal

$109.82

-0.09 (-0.08%)

, AXP

American Express

$119.52

1.07 (0.90%)

12:30
05/25/19
05/25
12:30
05/25/19
12:30
Periodicals
Big tech failed to dethrone credit cards, Barron's says »

Rather than being cut out…

PYPL

PayPal

$109.82

-0.09 (-0.08%)

AXP

American Express

$119.52

1.07 (0.90%)

MA

MasterCard

$251.40

1.57 (0.63%)

V

Visa

$162.72

1.2 (0.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 03

    Jun

  • 05

    Jun

  • 06

    Jun

  • 11

    Jun

  • 25

    Jun

  • 13

    Nov

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

, GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

07:20
05/25/19
05/25
07:20
05/25/19
07:20
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

GOOG

Alphabet

$1,132.99

-7.56 (-0.66%)

GOOGL

Alphabet Class A

$1,138.90

-5.98 (-0.52%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

AMBA

Ambarella

$38.28

1.07 (2.88%)

ON

ON Semiconductor

$17.68

-0.235 (-1.31%)

NKE

Nike

$82.12

-0.51 (-0.62%)

ADDYY

Adidas

$0.00

(0.00%)

UAA

Under Armour

$23.54

0.075 (0.32%)

UA

Under Armour

$20.91

0.08 (0.38%)

FL

Foot Locker

$44.39

-8.455 (-16.00%)

VMC

Vulcan Materials

$126.28

1.25 (1.00%)

FLR

Fluor

$29.04

0.18 (0.62%)

ACM

Aecom

$31.56

-0.03 (-0.09%)

X

U.S. Steel

$13.63

-0.08 (-0.58%)

AKS

AK Steel

$2.00

-0.155 (-7.21%)

NUE

Nucor

$51.12

-0.27 (-0.53%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$12.85

0.11 (0.86%)

F

Ford

$9.83

-0.02 (-0.20%)

GM

General Motors

$35.13

0.01 (0.03%)

HMC

Honda

$25.45

0.175 (0.69%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$118.54

1.16 (0.99%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 03

    Jun

  • 03

    Jun

  • 04

    Jun

  • 04

    Jun

  • 05

    Jun

  • 06

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 12

    Jun

  • 13

    Jun

  • 19

    Jun

  • 19

    Jun

  • 23

    Jun

  • 09

    Jul

  • 24

    Jul

  • 31

    Jul

  • 01

    Aug

  • 06

    Aug

  • 23

    Oct

  • 27

    Oct

UBER

Uber

$41.40

0.94 (2.32%)

17:49
05/24/19
05/24
17:49
05/24/19
17:49
Hot Stocks
Uber board director Ryan Graves intends to resign »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

APTO

Aptose Biosciences

$2.01

0.03 (1.52%)

17:46
05/24/19
05/24
17:46
05/24/19
17:46
Syndicate
Aptose Biosciences files for $40M at-the-market common stock offering »

Piper Jaffray and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

TRNX

Taronis Technologies

$0.48

0.004 (0.84%)

17:26
05/24/19
05/24
17:26
05/24/19
17:26
Syndicate
Breaking Syndicate news story on Taronis Technologies »

Taronis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:25
05/24/19
05/24
17:25
05/24/19
17:25
Hot Stocks
U.S. Energy discloses Nasdaq notice regarding delayed 10-Q filing »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

17:22
05/24/19
05/24
17:22
05/24/19
17:22
Periodicals
Apple sued over allegedly selling users' iTunes data, Bloomberg says »

Apple is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SPCB

SuperCom

$1.17

-0.005 (-0.43%)

17:21
05/24/19
05/24
17:21
05/24/19
17:21
Hot Stocks
SuperCom discloses Nasdaq notice regarding delayed 20-F filing »

SuperCom received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USEG

U.S. Energy

$0.45

0.0373 (9.10%)

17:20
05/24/19
05/24
17:20
05/24/19
17:20
Hot Stocks
U.S. Energy receives noncompliance notice from Nasdaq »

U.S. Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:18
05/24/19
05/24
17:18
05/24/19
17:18
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYOV

Myovant Sciences

$12.39

-0.465 (-3.62%)

17:17
05/24/19
05/24
17:17
05/24/19
17:17
Syndicate
Breaking Syndicate news story on Myovant Sciences »

Myovant Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$87.49

3.03 (3.59%)

, QGEN

Qiagen

$38.22

-0.255 (-0.66%)

16:57
05/24/19
05/24
16:57
05/24/19
16:57
Hot Stocks
Qiagen launches diagnostic for PIK3CA biomarkers in breast cancer »

Qiagen (QGEN) announced…

NVS

Novartis

$87.49

3.03 (3.59%)

QGEN

Qiagen

$38.22

-0.255 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 20

    Jun

  • 06

    Aug

AVH

Avianca

$3.96

0.91 (29.84%)

16:56
05/24/19
05/24
16:56
05/24/19
16:56
Periodicals
ANAC suspends flights, operations of Avianca Brasil, Reuters reports »

Brazil's ANAC said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$179.03

-0.64 (-0.36%)

16:53
05/24/19
05/24
16:53
05/24/19
16:53
Periodicals
Apple acquires startup Tueo Health, CNBC reports »

Apple has bought Tueo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

SHSP

SharpSpring

$16.37

-0.24 (-1.44%)

16:52
05/24/19
05/24
16:52
05/24/19
16:52
Syndicate
Breaking Syndicate news story on SharpSpring »

SharpSpring files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

CREG

China Recycling Energy

$0.48

0.005 (1.05%)

16:41
05/24/19
05/24
16:41
05/24/19
16:41
Syndicate
Breaking Syndicate news story on China Recycling Energy »

China Recycling Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.